Free Trial

Analysts Set Aquestive Therapeutics, Inc. (NASDAQ:AQST) Price Target at $10.14

Aquestive Therapeutics logo with Medical background

Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) have received a consensus recommendation of "Buy" from the seven ratings firms that are covering the stock, MarketBeat.com reports. Seven analysts have rated the stock with a buy rating. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $10.14.

A number of brokerages have recently weighed in on AQST. Oppenheimer began coverage on Aquestive Therapeutics in a research report on Monday, June 2nd. They set an "outperform" rating and a $7.00 price objective for the company. HC Wainwright restated a "buy" rating and set a $10.00 price objective on shares of Aquestive Therapeutics in a research report on Tuesday, June 17th.

Get Our Latest Stock Report on AQST

Aquestive Therapeutics Stock Up 9.0%

AQST stock traded up $0.33 during trading on Wednesday, reaching $4.01. The company's stock had a trading volume of 1,505,474 shares, compared to its average volume of 1,496,118. Aquestive Therapeutics has a 1 year low of $2.12 and a 1 year high of $5.80. The company has a market capitalization of $398.31 million, a P/E ratio of -6.80 and a beta of 1.97. The company's fifty day moving average is $3.04 and its 200-day moving average is $3.00.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.07). The business had revenue of $8.72 million during the quarter, compared to analyst estimates of $12.23 million. Analysts anticipate that Aquestive Therapeutics will post -0.46 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in AQST. Pale Fire Capital SE lifted its holdings in shares of Aquestive Therapeutics by 154.1% in the 1st quarter. Pale Fire Capital SE now owns 1,335,684 shares of the company's stock valued at $3,873,000 after acquiring an additional 809,928 shares during the last quarter. Bank of America Corp DE lifted its stake in Aquestive Therapeutics by 905.2% in the fourth quarter. Bank of America Corp DE now owns 690,284 shares of the company's stock worth $2,457,000 after purchasing an additional 621,614 shares during the last quarter. Stifel Financial Corp lifted its stake in Aquestive Therapeutics by 315.4% in the fourth quarter. Stifel Financial Corp now owns 398,561 shares of the company's stock worth $1,419,000 after purchasing an additional 302,617 shares during the last quarter. Nuveen LLC bought a new stake in Aquestive Therapeutics in the first quarter worth about $686,000. Finally, Harvey Capital Management Inc. lifted its stake in Aquestive Therapeutics by 86.8% in the first quarter. Harvey Capital Management Inc. now owns 499,570 shares of the company's stock worth $1,449,000 after purchasing an additional 232,180 shares during the last quarter. Institutional investors own 32.45% of the company's stock.

About Aquestive Therapeutics

(Get Free Report

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.

Featured Stories

Analyst Recommendations for Aquestive Therapeutics (NASDAQ:AQST)

Should You Invest $1,000 in Aquestive Therapeutics Right Now?

Before you consider Aquestive Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aquestive Therapeutics wasn't on the list.

While Aquestive Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead
3 Made in America Stocks Under $20 You Need to See!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines